Phase 3
18 Years
80 Years
18 Years
80 Years
Not Enrolling
Both
Myelodysplastic Syndromes
Both
Myelodysplastic Syndromes
Trial Information
Inclusion Criteria
- Eligible patients must have a diagnosis of myelodysplastic syndrome
- Life expectancy of at least 6 months.
- Patients must be able to adhere to the study visit schedule and other protocol
requirements.
- Patients must understand and voluntarily sign an informed consent document.
- Women of childbearing potential (WCBP) must agree to practice abstinence or to use
TWO methods of contraception beginning 4 weeks prior to the start of study medication
and throughout the course of treatment.
- Males must use barrier contraception when engaging in reproductive sexual activity
with women of childbearing potential.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
THAL-MDS-001
NCT ID:
NCT00050843
Start Date:
August 2001
Completion Date:
February 2004
Related Keywords:
- Myelodysplastic Syndromes
- Myelodysplastic Syndromes
- Preleukemia
Name | Location |
|---|---|
| Roswell Park Cancer Institute | Buffalo, New York 14263 |
| Mayo Clinic | Rochester, Minnesota 55905 |
| University of Rochester Cancer Center | Rochester, New York 14642 |
| Whittingham Cancer Center | Norwalk, Connecticut 06856 |
| Swedish Cancer Institute | Seattle, Washington 98104 |
| Comprehensive Cancer Centers of the Desert | Palm Springs, California 92262 |
| Western Pennsylvania Cancer Institute | Pittsburgh, Pennsylvania 15224 |
| Florida Cancer Specialists | Fort Myers, Florida 33901 |
| Southern Nevada Cancer Research Foundation | Las Vegas, Nevada 89106 |
| Oregon Health & Science University | Portland, Oregon 97201 |
| Scripps Cancer Center | La Jolla, California 92037 |
| Central Utah Medical Clinic | Provo, Utah 84604 |
| Desert Hematology Oncology Medical Group INC | Rancho Mirage, California 92270 |
| VA Connecticut Healthcare System | West Haven, Connecticut 06516 |
| Southeast Florida Hematology-Oncology | Ft. Lauderdale, Florida 33308 |
| Northwest Medical Specialists | Arlington Heights, Illinois 60004 |
| Oncology Associates | Cedar Rapids, Iowa 52403 |
| Beaumont Cancer Center | Royal Oak, Michigan 48073 |
| SMDC Health Systems | Duluth, Minnesota 55805 |
| Jackson Oncology Associates PLLC | Jackson, Mississippi 39202 |
| Hematology Oncology Consultants Inc | St. Louis, Missouri 63136 |
| Hematology Oncology Associates of NJ | Paramus, New Jersey 07652 |
| Summit Medical Group/Overlook Oncology Center | Summit, New Jersey 07901 |
| Memorial Sloan Kettering Cancer Ctr | New York, New York 10021 |
| VAMC Northport | Northport, New York 11768 |
| South Shore Hem-Onc Assoc. PA | Rockville Centre, New York 11570 |
| Staten Island Unversity Hospital | Staten Island, New York 10305 |
| Westchester County Medical Center | Valhalla, New York 10595 |
| Buffalo Medical Group PC | Williamsville, New York 14221 |
| Northwestern Carolina Hematology Oncology PA | Hickory, North Carolina 28602 |
| Wake Forest Univ School of Medicine | Winston Salem, North Carolina 27157-1082 |
| Oncology/Hematology Care Inc | Cincinnati, Ohio 45246 |
| Medical Oncology Associates | Kingston, Pennsylvania 18704 |
| Lancaster Cancer Center LTD | Lancaster, Pennsylvania 17605 |
| MCP Hahnemann University | Philadelphia, Pennsylvania 19129 |
| Texas Oncology PA-BMT Center | Dallas, Texas 75230 |
| InterMountain Hematology/Oncology | Salt Lake City, Utah 84122 |
| Yakima Regional CancerCenter | Yakima, Washington 98902 |
